RPCEC00000149
Completed
Phase 4
Evaluation of the safety and effectiveness of ior EPOCIM® in the management of anemia of the preterm infant.
Center of Molecular Immunology(CIM)0 sites121 target enrollmentFebruary 26, 2013
ConditionsAnemia of newborn preterm
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Anemia of newborn preterm
- Sponsor
- Center of Molecular Immunology(CIM)
- Enrollment
- 121
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Preterm patients with weight \= 1500 g and gestational age \< 34 weeks (determined by the method of date of last menstruation. 2\.Patients whose parent or responsible family member has granted your consent to participation in the study in writing.
- •3\.Patients with more than 15 days old.
- •4\.Patients with an intake of at least 50 mL/kg/day of maternal and/or artificial milk.
Exclusion Criteria
- •1\.Patients with diagnosis of hemorrhagic or hemolytic disease.
- •2\.Patients with a diagnosis of major congenital malformation requiring transfer to another service of Neonatology.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of safety and effectiveness regarding intraocular cyclophotocoagulation for refractory glaucomaRefractory terminal glaucoma Glaucoma absolutumJPRN-UMIN000027090Sato Yuya Eye Clinic20
Completed
Phase 2
Assessment of the Results of Inovo Sense Smile and Inovo Sense Style Filler Injections to Correction Nasolabial FoldsIRCT20220723055530N1Khosro Medisa Teb Company30
Completed
Not Applicable
Evaluation of the safety and effectiveness of the MID-C/ApiFix system in adolescent idiopathic scoliosis.Spinal curvature1002837710005944NL-OMON43676Vrije Universiteit Medisch Centrum33
Not yet recruiting
Phase 4
euroEPO in mild-moderate Alzheimer's disease amnesic variantmild-moderate Alzheimer's diseaseAlzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersRPCEC00000410Center of Molecular Immunology (CIM)1,456
Active, not recruiting
Not Applicable
Safety and effectiveness clinical evaluation of the range of injectable medical devices HYDRAGEL C in facial aesthetic treatmentSubjects across groups present with moderate to severe facial aesthetic concerns, including peri-oral lines, nasolabial folds, lip volume deficits, and cheeks/cheekbones volume deficit, as gauged by various dermatological scalesSkin and Connective Tissue DiseasesISRCTN13586698ouna Aesthetics75